Generex biotechnology aerosol formulation patent accepted in New Zealand

Published: 8-May-2003

North American drug delivery r&d company Generex Biotechnology has received a Notice of Acceptance from the Intellectual Property office of New Zealand. The patent relates to aerosol formulations for buccal and pulmonary applications.


North American drug delivery r&d company Generex Biotechnology has received a Notice of Acceptance from the Intellectual Property office of New Zealand. The patent relates to aerosol formulations for buccal and pulmonary applications.

'This acceptance demonstrates that our foreign patent strategy is progressing well, along with our US strategy,' said Anna Gluskin, president and ceo of Generex. 'We believe this will enhance Generex's potential for licensing the marketing rights for our clinical portfolio.' Generex holds 15 foreign patents along with 56 patent applications pending in eight countries.

You may also like